Danish biopharma company Lundbeck (CPH: LUN) posted a robust 18% revenue increase in the third quarter of 2024, reaching 5.7 billion Danish kroner ($815 million). Earnings per share rose to 0.78 kroner, marking a 15% year-on-year improvement, while adjusted earnings per share increased by 11%.
Growth was bolstered by strategic brands, which contributed to 75% of quarterly revenue. Key drivers included a significant 74% growth for Vyepti (eptinezumab), alongside solid performance from Rexulti (brexpiprazole) and Brintellix (vortioxetine), particularly in the USA.
On the down side, performance of mature brands softened, declining by 7% due to generic competition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze